Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men - A suggested update

Aging Male

Volumn 16, Issue 4, 2013, Pages 143-150

  Lunenfeld, Bruno ^a   Mskhalaya, George ^b   Kalinchenko, Svetlana ^c   Tishova, Yulia ^c  

^a BAR ILAN UNIVERSITY   (Israel)

^b Center for Reproductive Medicine MAMA   (Russian Federation)

^c PEOPLES FRIENDSHIP UNIVERSITY OF RUSSIA   (Russian Federation)

Author keywords

Late onset hypogonadism; Men; Testosterone

Indexed keywords

GLUCOCORTICOID; OPIATE; TESTOSTERONE;

ANDROGEN DEFICIENCY; ANDROGEN THERAPY; BODY COMPOSITION; BONE DENSITY; COGNITION; DEPRESSION; GLYCEMIC CONTROL; HUMAN; HYPOGONADISM; LABORATORY DIAGNOSIS; LOWER URINARY TRACT SYMPTOM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; SEXUAL FUNCTION; THERAPY;

HYPOGONADISM; AGE OF ONSET; AGED; ANDROGENS; DISEASE MANAGEMENT; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; MONITORING, PHYSIOLOGIC; TESTOSTERONE;

EID: 84890055547     PISSN: 13685538     EISSN: 14730790     Source Type: Journal    
DOI: 10.3109/13685538.2013.853731     Document Type: Review

References (120)

1. Lunenfeld B, Arver S, Moncada I, et al. How to help the aging male? Current approaches to hypogonadism in primary care. Aging Male 2012;15:187-97
2. Trinick TR, Feneley MR, Welford H, Carruthers M. International web survey shows high prevalence of symptomatic testosterone deficiency in men. Aging Male 2011;14:10-15
3. AACE Hypogonadism Task Force. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the evaluation and treatment of hypogonadism in adult male patients 2002. Endocr Pract 2002;8:439-56
4. Morley JE, Perry 3rd HM, Kevorkian RT, Patrick P. Comparison of screening questionnaires for the diagnosis of hypogonadism. Maturitas 2006;20;53:424-9
5. Chen W, Liu ZY, Wang LH, et al. Are the Aging Male's Symptoms (AMS) scale and the Androgen Deficiency in the Aging Male (ADAM) questionnaire suitable for the screening of late-onset hypogonadism in aging Chinese men? Aging Male 2013;16:92-6
6. Rabah DM, Altaweel W, Arafa MA. Clinical assessment and validation of an Arabic Aging Male Symptoms questionnaire in patients with androgen deficiency. Aging Male 2011;14:33-6
7. Zengerling F, Schrader AJ, Cronauer MV, et al. The ''Aging Males' Symptoms'' Scale (AMS): Predictive value for lowered circulating androgens. Aging Male 2012;15:253-7
8. Lee CP, Jiang JR, Chen Y, et al. The ''Aging Males' Symptoms'' (AMS) Scale assesses depression and anxiety. Aging Male 2013;16:97-101
9. Moore C, Huebler D, Zimmermann T, et al. The Aging Males' Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol 2004;46:80-7
10. Nakamura M, Fujimura T, Nagata M, et al. Association between lower urinary tract symptoms and sexual dysfunction assessed using the core lower urinary tract symptom score and International Index of Erectile Function-5 questionnaires. Aging Male 2012;15: 111-14
11. Behre HM, Tammela TL, Arver S, et al. A randomized, doubleblind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male 2012;15:198-207
12. Hermanns-Lê T, Scheen A, Piérard GE. Acanthosis nigricans associated with insulin resistance: Pathophysiology and management. Am J Clin Dermatol 2004;5:199-203
13. Saad F, Aversa A, Isidori AM, et al. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: A review. Curr Diabetes Rev 2012;8:131-43
14. Corona G, Rastrelli G, Vignozzi L, et al. Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract Res Clin Endocrinol Metab 2011;25:337-53
15. Corona G, Rastrelli G, Morelli A, et al. Hypogonadism and metabolic syndrome. J Endocrinol Invest 2011;34:557-67
16. Brunton SA, Sadovsky R. Late-onset male hypogonadism and testosterone replacement therapy in primary care. J Fam Pract 2010;59:1-8
17. Bhasin S, Cunningham GR, Hayes FJ, et al.; Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-59
18. Lejeune H, Huyghe E, Droupy S. [Hypoactive sexual desire and testosterone deficiency in men]. Prog Urol 2013;23:621-8
19. Lunenfeld B, Arver S, Moncada I, et al. How to help the aging male? Current approaches to hypogonadism in primary care. Aging Male. 2012;15:187-97
20. Wu FC, Tajar A, Beynon JM, et al.; EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363:123-35
21. Spetz Holm AC, Fredrikson MG, Hammar ML. Symptoms of testosterone deficiency in early middle aged men. Aging Male 2012;15:78-84
22. Surampudi PN, Wang C, Swerdloff R. Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy. Int J Endocrinol 2012;2012:625434
23. Kaplan SA, O'Neill E, Lowe RS, et al. Testosterone in aging men with benign prostatic hyperplasia: Data from the Proscar Long-term Efficacy and Safety Study (PLESS). Aging Male 2013;16:48-51
24. Schatzl G, Brossner C, Schmid S, et al. Endocrine status in elderly men with lower urinary tract symptoms: Correlation of age, hormonal status, and lower urinary tract function. The Prostate Study Group of the Austrian Society of Urology. Urology 2000;55: 397-402
25. Higano C. Androgen deprivation therapy: Monitoring and managing the complications. Hematol Oncol Clin North Am 2006;20: 909-23
26. Choong K, Basaria S. Emerging cardiometabolic complications of androgen deprivation therapy. Aging Male 2010;13:1-9
27. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294:238-44
28. Joly F, Alibhai SM, Galica J, et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with non metastatic prostate cancer. J Urol 2006;176: 2443-7
29. Mohile SG, Bylow K, Dale W, et al. A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer 2007;109: 802-10
30. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76
31. Araujo AB, Dixon JM, Suarez EA, et al. Endogenous testosterone and mortality in men: A systematic review and meta-analysis. J Clin Endocrinol Metab 2011;96:3007-19
32. Hyde Z, Norman PE, Flicker L, et al. Low free testosterone predicts mortality from cardiovascular disease, but not other causes. The Health in Men Study. J Clin Endocrinol Metab 2012;97:179-89
33. Shores MM, Smith NL, Forsberg CW, et al. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 2012;97:2050-8
34. Yeap Bu B. Testosterone therapy and mortality in US veterans. Asian J Androl 2012;14:667-8
35. Wu WC. Frederick caveat emptor: Does testosterone treatment reduce mortality in men? J Clin Endocrinol Metab 2012;97:1884-6
36. Isidori AM, Lenzi A. Risk factors for androgen decline in older males: Lifestyle, chronic diseases and drugs. J Endocrinol Invest 2005;28:14-22
37. Hyde Z, Norman PE, Flicker L, et al. Low free testosterone predicts mortality from cardiovascular disease but not other causes: The Health in Men Study. J Clin Endocrinol Metab 2012;97:179-89
38. Corona G, Rastrelli G, Monami M, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: A meta-analytic study. Eur J Endocrinol 2011;165:687-701
39. Cattabiani C, Basaria S, Ceda GP, et al. Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men. J Endocrinol Invest 2012;35:104-20
40. Lee DM, Tajar A, Pye SR, et al. The EMAS Study Group. Association of hypogonadism with vitamin D status: The European Male Ageing Study. Eur J Endocrinol 2012;166:77-85
41. Pilz S, Frisch S, Koertke H, et al. Effect of vitamin D supplementation on testosterone levels in men. Horm Metab Res 2011;43: 223-5
42. Wehr E, Pilz S, Boehm BO, et al. Association of vitamin D status with serum androgen levels in men. Clin Endocrinol 2010;73:243-8
43. Bremner AP, Feddema P, Leedman PJ, et al. Age-related changes in thyroid function: A longitudinal study of a community-based cohort. J Clin Endocrinol Metab 2012;97:1554-62
44. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002;87:489-99
45. Brochmann H, Bjoro T, Gaarder PI, et al. Prevalence of thyroid dysfunction in elderly subjects. A randomized study in a Norwegian rural community (Naeroy). Acta Endocrinol (Copenh) 1988;117: 7-12
46. Boucai L, Hollowell JG, Surks MI. An approach for development of age-, gender-, and ethnicity-specific thyrotropin reference limits. Thyroid 2011;21:5-11
47. Bremner AP, Feddema P, Leedman PJ, et al. Age-related changes in thyroid function: A longitudinal study of a community-based cohort. J Clin Endocrinol Metab 2012;97:1554-62
48. Dobs AS, Few 3rd WL, Blackman MR, et al. Serum hormones in men with human immunodeficiency virus-associated wasting. J Clin Endocrinol Metab 1996;81:4108-12
49. Khera M, Bhattacharya RK, Blick G, et al. The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS). Aging Male 2012;15: 14-21
50. Martens HF, Sheets PK, Tenover JS, et al. Decreased testosterone levels in men with rheumatoid arthritis: Effect of low dose prednisone therapy. J Rheumatol 1994;21:1427-31
51. Aloisi AM, Aurilio C, Bachiocco V, et al. Endocrine consequences of opioid therapy. Psychoneuroendocrinology 2009;34:162-8
52. Reddy RG, Aung T, Karavitaki N, Wass JAH. Opioid induced hypogonadism. BMJ 2010;341:605-60
53. Schooling CM, Au Yeung SL, Freeman G, Cowling BJ. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med 2013; 11:57
54. Diver MJ, Imtiaz KE, Ahmad AM, et al. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middleaged men compared with those in young men. Clin Endocrinol (Oxf) 2003;58:710-17
55. Bhasin S, Pencina M, Jasuja GK, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab 2011;96:2430-9
56. Citron JT, Ettinger B, Rubinoff H, et al. Prevalence of hypothalamic- pituitary imaging abnormalities in impotent men with secondary hypogonadism. J Urol 1996;155:529-33
57. Bunch TJ, Abraham D, Wang S, Meikle AW. Pituitary radiographic abnormalities and clinical correlates of hypogonadism in elderly males presenting with erectile dysfunction. Aging Male 2002;5: 38-46
58. Araujo AB, O'Donnell A, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: Estimates from the Massachusetts male aging study. J Clin Endocrinol Metab 2004;89:5920-6
59. Vermeulen A. Hormonal cut-offs of partial androgen deficiency: A survey of androgen assays. J Endocrinol Invest 2005;28:28-31
60. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91:1995-2010
61. Kacker R, Hornstein A, Morgentale A. Testosterone by direct and calculated measurement versus equilibrium dialysis in a clinical population. Aging Male 2013 (Epub ahead of print)
62. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-72
63. Rosner W, Auchus RJ, Azziz R, et al. Utility, limitations, and pitfalls in measuring testosterone: An Endocrine Society Position Statement. J Clin Endocrinol Metab 2007;92:405-13
64. Holm AC, Fredrikson MG, Theodorsson E, et al. Change in testosterone concentrations over time is a better predictor than the actual concentrations for symptoms of late onset hypogonadism. Aging Male 2011;14:249-56
65. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006;91:4335-43
66. Behre HM, Tammela TL, Arver S, et al.; European Testogel- Study Team. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related qualityof- life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male 2012;15:198-207
67. Berglund LH, Prytz HS, Perski A, Svartberg J. Testosterone levels and psychological health status in men from a general population: The Tromsø study. Aging Male 2011;14:37-41
68. Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved.Eur J Endocrinol 2011;165:675-85
69. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85:2670-7
70. Aversa A, Bruzziches R, Francomano D, et al. Effects of longacting testosterone undecanoate on bone mineral density in middleaged men with late-onset hypogonadism and metabolic syndrome: Results from a 36 months controlled study. Aging Male 2012;15: 96-102
71. Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men a meta-analysis. Clin Endocrinol (Oxf) 2005;63: 280-93
72. Bhasin S, Calof OM, Storer TW, et al. Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 2006;2:146-59
73. Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late onset hypogonadism and metabolic syndrome: Results from a 24-months, randomized double blind placebo-controlled study. J Sex Med 2010;7: 3495-503
74. Saad F, Haider A, Doros G, Traish A. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring) 2013;21:1975-81
75. Yassin AA, Doros G. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clin Obesity 2013;3:73-83
76. Francomano D, Bruzziches R, Ilacqua A, et al. Effects of five-years treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. Urology 2013 (Epub ahead print).
77. Krasnoff JB, Basaria S, Pencina MJ, et al. Free testosterone levels are associated with mobility limitation and physical performance in community-dwelling men: The Framingham Offspring Study. J Clin Endocrinol Metab 2010;95:2790-9
78. Meier C, Nguyen TV, Handelsman DJ, et al. Endogenous sex hormones and incident fracture risk in older men: The Dubbo Osteoporosis Epidemiology Study. Arch Intern Med 2008;168: 47-54
79. Drake MT, Murad MH, Mauck KF, et al. Risk factors for low bone mass-related fractures in men: A systematic review and metaanalysis. J Clin Endocrinol Metab 2012;97:1861-70
80. Kanis JA, Oden A, Johansson H, et al. FRAX and its applications to clinical practice. Bone 2009;44:734-43
81. Watts NB, Adler RA, Bilezikian JP, et al.; Endocrine Society. Osteoporosis in men: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97:1802-22
82. Orwoll E, Lambert LC, Marshall LM, et al. Endogenous testosterone levels, physical performance, and fall risk in older men. Arch intern Med 2006;166:2124-31
83. Isidori AM, Giannetta E, Gianfrilli D, et al. Effects of testosterone on sexual function in men: Results of a meta-analysis. Clin Endocrinol (Oxf) 2005;63:381-94
84. Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 2003;6:94-9
85. Zitzmann M, Mattern A, Hanisch J, et al. IPASS: A study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med 2013;10:579-88
86. Tan WS, Ng CJ, Khoo EM, et al. The triad of erectile dysfunction, testosterone deficiency syndrome and metabolic syndrome: Findings from a multi-ethnic Asian men study (The Subang Men's Health Study). Aging Male 2011;14:231-6
87. Kapoor D, Aldred H, Clark S, et al. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: Correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007;30:911-17
88. Akira Tsujimura, Yasushi Miyagawa, Kentaro Takezawa, et al. Is low testosterone concentration a risk factor for metabolic syndrome in healthy middle-aged men?.Urology 2013;82:814-19
89. Kalinchenko SY, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: The double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) 2010;73:602-12
90. Zitzmann M, Mattern A, Hanisch J, et al. IPASS: A study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med 2013;10:579-88
91. Saad F, Aversa A, Isidori AM, Gooren LJ. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: A review. Curr Diabetes Rev 2012;8:131-43
92. Yassin AA, Doros G. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clinical obesity 2013;3:73-83
93. Rodríguez-Tolrà J, Torremude Bareda J, Del Rio L, et al. Effects of testosterone treatment on body composition in males with testosterone deficiency syndrome. Aging Male 2013 (Epub ahead of print)
94. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009;30:726-33
95. Hackett G, Cole N, Bhartia M, et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Int J Clin Pract 2013 (in press)
96. Strollo F, Strollo G, Morè M, et al. Low-intermediate dose testosterone replacement therapy by different pharmaceutical preparations improves frailty score in elderly hypogonadal hyperglycaemic patients. Aging Male 2013;16:33-7
97. Akishita M, Hashimoto M, Ohike Y, et al. Low testosterone level is an independent determinant of endothelial dysfunction in men. Hyperten Res 2007;30:1029-34
98. Muller M, van den Beld AW, Bots ML, et al. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation 2004;109:2074-9
99. Kang SM, Jang Y, Kim JY, et al. Effect of oral administration of testosterone on brachial arterial vasoreactivity in men with coronary artery disease. Am J Cardiol 2002;89:862-4
100. Zitzmann M, Vorona E, Wenk M, et al. Testosterone administration decreases carotid artery intima media thickness as indicator of vascular damage in middle-aged overweight men. J Androl 2008;29(Suppl 1):54-5
101. Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late onset hypogonadism and metabolic syndrome: Results from a 24-months, randomized double blind placebo-controlled study. J Sex Med 2010;7: 3495-503
102. Zarrouf FA, Artz S, Griffith J, et al. Testosterone and depression: Systematic review and meta-analysis. J Psychiatr Pract 2009;15: 289-305
103. Giltay EJ, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med 2010;7:2572-82
104. Khera M, Bhattacharya RK, Blick G, et al. The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS). Aging Male 2012;15:14-21
105. Morley JE, Kaiser F, Raum WJ, et al. Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: Progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone. Proc Natl Acad Sci USA 1997;94:7537-42
106. Maggio M, Dall'Aglio E, Lauretani F, et al. The hormonal pathway to cognitive impairment in older men. J Nutr Health Aging 2012;16:40-54
107. Janowsky JS. Thinking with your gonads: Testosterone and cognition. Trends Cogn Sci 2006;10:77-82
108. Etgen T, Sander D, Bickel H, Förstl H. Mild cognitive impairment and dementia: The importance of modifiable risk factors. Dtsch Arztebl Int 2011;108:743-50
109. Pearl JA, Berhanu D, François N, et al. Testosterone supplementation does not worsen lower urinary tract symptoms. J Urol 2013;190:1828-33
110. Shigehara K, Sugimoto K, Konaka H, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: A randomised controlled study. Aging Male 2011;14:53-8
111. Roddam AW, Allen NE, Appleby P, Key TJ; Endogenous Hormones and Prostate Cancer Collaborative Group. Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008;100: 170-83
112. Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: A systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95:2560-75
113. Zitzmann M, Mattern A, Hanisch J, et al. IPASS: A study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med 2013;10:579-88
114. Bhasin S, Cunningham GR, Hayes FJ, et al. Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-59
115. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen in men with and without prostate disease. JAMA 1992;267:2215-20
116. Punglia RS, Cullen J, McLeod DG, et al. Prostate-specific antigen velocity and the detection of Gleason score 7 to 10 prostate cancer. Cancer 2007;110:1973-8
117. Bhasin S, Cunningham GR, Hayes FJ, et al. 2006 Testosterone therapy in adult men with androgen deficiency syndromes: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2010;95:2536-59
118. Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: A systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95:2560-75
119. Dobs AS, Meikle AW, Arver S, et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999;84:3469-78
120. Jones TH, Saad F. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis 2009;207:318-27.